title: Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.
abstract: Formation of antibodies against botulinum toxin type A has been observed following treatment of Cervical Dystonia (CD). We present the immunological findings from two 12-week Phase III prospective, randomized, double-blind, single-dose, placebo-controlled studies (Study 1, n = 116; Study 2, n = 136). Patients in both studies were administered abobotulinumtoxinA 500U or placebo intramuscularly at baseline. Patients could receive up to three or four additional treatments (250-1000U) in an open-label follow-up period. Blood samples were collected at baseline and during treatment to test for antibodies to abobotulinumtoxinA using a radioimmunoprecipitation assay (Study 2 only) and a mouse protection assay. Loss of response was predefined using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score at 4 weeks following injection. No subjects in Study 1 and one individual in Study 2 developed neutralizing antibodies (nABs) during the double-blind treatment phase; the individual who developed immunoresistance had received botulinum toxin type A treatment prior to the study and did not respond to treatment. Two subjects demonstrated a change in nAB status during open-label treatment and overall responsiveness was maintained in these patients. In conclusion, the development of immunoresistance was rare and, in the presence of circulating nABs, patients may still gain benefit from intramuscular abobotulinumtoxinA treatment.
authors.affiliation: Ipsen, Brisbane, CA 94005, USA. Chandra.Coleman@ipsen.com
authors.forename: Chandra
authors.initials: C
authors.lastname: Coleman
authors.forename: Jean
authors.initials: J
authors.lastname: Hubble
authors.forename: Joseph
authors.initials: J
authors.lastname: Schwab
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Beffy
authors.forename: Philippe
authors.initials: P
authors.lastname: Picaut
authors.forename: Carles
authors.initials: C
authors.lastname: Morte
mesh_terms: D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000097:blood; D019274:Botulinum Toxins, Type A / Q000276:immunology* / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000276:immunology* / Q000627:therapeutic use*; D012720:Severity of Illness Index; D014103:Torticollis / Q000188:drug therapy* / Q000276:immunology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000906:Antibodies; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA